On August 3 2023, PARATEK PHARMACEUTICALS ($NASDAQ:PRTK) revealed their financial results for the second quarter of FY2023, ending June 30 2023. Revenue grew 38.1% year on year, amounting to USD 38.1 million. Additionally, their net income was USD -14.6 million, a notable improvement from the -17.6 million recorded in the corresponding period of the previous year.
On Thursday, their stock opened at $2.2 and closed at the same price, down by 0.9% from the prior closing price of $2.2. The company’s CEO Athene Madison was optimistic about the results and said that they had made significant progress in advancing their product pipeline over the quarter and that they remain committed to creating long term value for their shareholders. Overall, PARATEK PHARMACEUTICALS reported strong earnings results for the quarter, and investors are optimistic about their future prospects given the company’s progress in developing new drugs. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Paratek Pharmaceuticals. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Paratek Pharmaceuticals. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Paratek Pharmaceuticals. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Paratek Pharmaceuticals are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
Analysis – Paratek Pharmaceuticals Intrinsic Value Calculation
At GoodWhale, we analyze the financials of public companies to help investors make informed decisions. Our proprietary Valuation Line determines the fair value of a company’s stock by considering its fundamentals and accounting for other factors that can affect its value. We recently conducted an analysis of PARATEK PHARMACEUTICALS and our Valuation Line suggests that the fair value of its share is around $7.4. However, the stock is currently being traded at $2.2, which is greatly undervalued by 70.1%. This signals to us that it may be a great investment opportunity for investors. More…
Risk Rating Analysis
Star Chart Analysis
The competition in the biotechnology industry is fierce. Paratek Pharmaceuticals Inc is up against some stiff competition from Innovation1 Biotech Inc, InVivo Therapeutics Holdings Corp, and Gene Biotherapeutics Inc. All of these companies are working hard to develop new and innovative treatments for a variety of diseases.
– Innovation1 Biotech Inc ($OTCPK:IVBT)
Innovation1 Biotech Inc has a market cap of 1.6M as of 2022, a Return on Equity of -5.58%. The company is engaged in the research and development of pharmaceutical and biotechnology products. It has developed a platform that uses human cells to screen for potential new drugs and to study the mechanisms of disease. The company has also developed a portfolio of products in the areas of cancer, infectious diseases, and inflammation.
– InVivo Therapeutics Holdings Corp ($NASDAQ:NVIV)
InVivo Therapeutics Holdings Corp is a development stage biomedical company that focuses on the treatment of spinal cord injuries. The company was founded in 2005 and is headquartered in Cambridge, Massachusetts. As of 2022, InVivo Therapeutics has a market cap of 4.42M and a Return on Equity of -75.97%.
InVivo Therapeutics is working on a bioresorbable scaffold device that is implanted around the injured area of the spinal cord to provide support and protection while the cord heals. The company is also developing an implantable neurostimulation device to deliver electrical stimulation to the spinal cord to promote regeneration and functional recovery.
– Gene Biotherapeutics Inc ($OTCPK:CRXM)
Gene Biotherapeutics Inc is a company that focuses on the development of gene therapies. The company has a market cap of 6.49k as of 2022 and a return on equity of 10.16%. The company’s focus on gene therapies allows it to develop treatments for a variety of diseases and conditions. The company’s products are designed to target the root cause of a disease or condition, which allows for more effective and long-lasting treatments. The company’s products are also designed to be safe and effective for all patients, regardless of their age or health status.
Paratek Pharmaceuticals reported strong financial results for the second quarter of FY2023, ending June 30 2023. Revenue increased 38.1% year over year to USD 38.1 million, and net income improved by 2 million, from -17.6 million to -14.6 million. The company appears to have good growth potential, and could be a good investment opportunity for those seeking a long-term return. Investors should look at the company’s business strategy and watch for any developments that could impact its performance in the future.